Systematic Review: Sequential Rescue Therapy in Severe Ulcerative Colitis: Do the Benefits Outweigh the Risks?

Area of Science:

• Gastroenterology
• Clinical Pharmacology
• Evidence-Based Medicine

Background:

• Limited medical management options exist for acute severe steroid-refractory ulcerative colitis (UC).
• Recent guidelines advise against sequential rescue therapy after initial salvage treatment failure.
• This review assesses sequential infliximab (IFX) and calcineurin inhibitor (cyclosporine/tacrolimus) use in steroid-refractory UC.

Purpose of the Study:

• To evaluate the efficacy and safety of sequential rescue therapy in acute severe steroid-refractory UC.
• To analyze outcomes including response, remission, adverse events, and colectomy rates.
• To inform clinical decision-making regarding sequential therapy in UC management.

Main Methods:

• Systematic literature search for studies on IFX and CsA/Tac in acute severe UC.
• Inclusion of ten studies with 314 participants.
• Analysis of short-term response, remission, adverse drug reactions, serious infections, mortality, and colectomy at 3 and 12 months.

Main Results:

• Sequential therapy achieved short-term response in 62.4% and remission in 38.9% of patients.
• Colectomy rates were 28.3% at 3 months and 42.3% at 12 months.
• Adverse events occurred in 23.0%, including serious infections (6.7%) and 1% mortality.

Conclusions:

• Sequential therapy for steroid-refractory UC may have a lower risk than previously thought.
• Evidence quality is very low, warranting caution and further investigation.
• Sequential therapy decisions should be made at specialized centers, not solely based on current guidelines.